Articles by Andrew Moreno
Azercabtagene zapreleucel is an allogeneic CD-19-targeting therapy combining lymphodepletion chemotherapy with interleukin-2.
The hepcidin mimetic increased hematocrit control and reduced both phlebotomy need and symptoms in a phase 2 trial.
Thrombosis history was not predictive of overall survival in patients with pulmonary hypertension risk and PV, a study found.
The oral agent exhibited promising hemoglobin response performance and safety in this stage of an ongoing phase 2/3 study.
The first-in-class agent operates by increasing both von Willebrand factor and factor VIII levels in patients.
Immune thrombocytopenia featured most prominently at the Meeting but new data was presented for several forms of the disease.
In findings arterial thrombosis carried worse overall survival than venous thrombosis in this patient population.
Clinical trials are ongoing to evaluate this orally available, selective inhibitor of XPO1 as part of combination regimens.
The panel's discussion, moderated by Neil Love, MD, dove especially into the nuances of using avapritinib and ruxolitinib.
Neil Love, MD, has moderated an expert panel discussing current practice and recent data behind these treatments for NHL.
Anthony Sochet, MD, MS, on Knowledge Gaps Affecting Pediatric Inpatient Thromboprophylaxis Decisions
Clinical data is limited in areas such as how to evaluate bleeding risk and when to apply mechanical thromboprophylaxis.
Clinical trials are ongoing of linvoseltamab as monotherapy or in combination therapy for relapsed or refractory disease.
This bispecific antibody is under investigation for multiple types of B-cell non-Hodgkin lymphoma in ongoing clinical trials.
Overall survival, nonrelapse mortality, and relapse rates were also assessed in the phase 2 trial which had these results.
This agent has already received indications in Japan for relapsed or refractory DLBCL and other large B-cell lymphomas.
The oral agent is currently under evaluation in a first-in-human phase I trial for use in relapsed or refractory disease.
Patients with follow-up of one month or longer saw hemolysis marker improvement and reported no vaso-occlusive crises.
Approval issued for adults ineligible for CAR T-cell therapy or autologous transplant after two or more systemic therapies.
In a phase III trial 90% of evaluable patients were free of severe vaso-occlusive crisis for at least 12 consecutive months.
A prospective study involved ultrasound imaging of patients' carotid arteries to evaluate for structural changes.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.